{"title":"Comparison of three immunosuppressive regimens in kidney transplantation: a single-centre randomised study.","authors":"M Hourmant, J P Soulillou, J Guenel","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Three immunosuppressive regimens have been compared: conventional treatment including anti-thymocyte globulin (ATG) (32 patients) with cyclosporine (Cys) alone (21 patients), sequential combination of ATG with Cys (35 patients). Actuarial graft survivals were: ATG 73 per cent, Cys alone 88 per cent at nine months and ATG/Cys 92 per cent at one to two years. Transplant function was significantly worse with Cys as initial treatment compared with that in controls, while it was similar with ATG/Cys. The Cys dose used was low and no severe infection nor immunoglobulin abnormalities were noticed. Corticosteroids were withdrawn with both Cys protocols, except for rejection treatment.</p>","PeriodicalId":77886,"journal":{"name":"Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress","volume":"21 ","pages":"982-6"},"PeriodicalIF":0.0000,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Three immunosuppressive regimens have been compared: conventional treatment including anti-thymocyte globulin (ATG) (32 patients) with cyclosporine (Cys) alone (21 patients), sequential combination of ATG with Cys (35 patients). Actuarial graft survivals were: ATG 73 per cent, Cys alone 88 per cent at nine months and ATG/Cys 92 per cent at one to two years. Transplant function was significantly worse with Cys as initial treatment compared with that in controls, while it was similar with ATG/Cys. The Cys dose used was low and no severe infection nor immunoglobulin abnormalities were noticed. Corticosteroids were withdrawn with both Cys protocols, except for rejection treatment.